FibroScint
Phase 1- Indications
- Left ventricular assist device thrombosis, Deep vein thrombosis, Pulmonary embolism, Acute coronary syndrome
Company intelligence / Profile preview
Capella Imaging, Inc.
St. Louis, Missouri, United Statescapellaimaging.net ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
FDA cleared the IND application for Kit for the Preparation of 99m-Tc FibroScint Injection for the detection of cardiovascular thrombus in August 2024[2]
- Therapeutic areas
- Cardiovascular
- Modalities
- Nuclear diagnostic imaging agentsradiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
NorthStar Medical Technologies, LLC
Beyond the preview
Go deeper on Capella Imaging, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Capella Imaging, Inc..